Exelixis Inc (EXEL):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9958)
◆英語タイトル:Exelixis Inc (EXEL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9958
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:86
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Exelixis Inc (Exelixis) is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company has three product candidates: Cometriq (Cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma; and Cotellic (cobimetinib) is developed in combination with vemurafenib for the treatment of patients with mutation-positive advanced melanoma. The company also enters into collaborative partnerships with pharmaceutical and biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in South San Francisco, California, the US.

Exelixis Inc (EXEL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Exelixis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Exelixis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Exelixis Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Exelixis Enters into Agreement with Roche 11
Exelixis Enters into Agreement with Bristol-Myers Squibb 12
Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 13
Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 15
Licensing Agreements 17
Exelixis Enters into Licensing Agreement with Invenra 17
Exelixis Enters into Licensing Agreement with Stemsynergy Therapeutics 18
Takeda Pharma Enters into Licensing Agreement with Exelixis 19
Ipsen Amends Licensing Agreement with Exelixis 20
Equity Offering 22
Exelixis Raises USD155 Million in Public Offering of Shares 22
Exelixis Completes Public Offering Of Shares For US$80 Million 23
Exelixis Completes Public Offering Of Common Stock For US$147 Million 24
Exelixis Completes Public Offering Of Common Stock For US$69 Million 25
Debt Offering 27
Exelixis Completes Public Offering Of Senior Convertible Notes Due 2019 For US$288 Million 27
Exelixis Inc – Key Competitors 29
Exelixis Inc – Key Employees 30
Exelixis Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Aug 01, 2018: Exelixis announces second quarter 2018 financial results and provides corporate update 32
May 02, 2018: Exelixis Reports First Quarter 2018 Financial Results 35
Feb 26, 2018: Exelixis Reports Fourth Quarter and Full Year 2017 Financial Results 38
Nov 01, 2017: Exelixis Announces Third Quarter 2017 Financial Results and Provides Corporate Update 41
Aug 02, 2017: Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update 44
May 01, 2017: Exelixis Announces First Quarter 2017 Financial Results and Provides Corporate Update 47
Feb 27, 2017: Exelixis Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 50
Corporate Communications 54
Apr 09, 2018: Exelixis Elects Dr. Maria Freire to Its Board of Directors 54
Legal and Regulatory 55
Jan 09, 2017: Genentech withdraws counterclaim against Exelixis 55
Product News 56
10/16/2017: Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma 56
04/19/2018: Drug Combination Targeting Heat Shock Protein 90 and BRAF is Safe and Effective in Advanced Melanoma Patients 58
Product Approvals 59
Sep 08, 2017: Ipsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adults 59
Aug 16, 2017: Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX for the Treatment of Previously Untreated Advanced Kidney Cancer 61
Jul 10, 2017: Kidney Cancer UK delighted NICE recommends cabozantinib on NHS for kidney cancer patients 63
Jul 10, 2017: Life-extending tablet for advanced kidney cancer, Cabometyx (cabozantinib), approved by NICE for routine access by English and Welsh patients 64
Jun 12, 2017: Scotland first in UK to make Cabometyx (cabozantinib) routinely available for individuals living with advanced kidney cancer 65
Mar 06, 2017: Exelixis’ Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma 66
Clinical Trials 67
Nov 21, 2017: Exelixis Announces Phase 3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma to be Presented at 2018 Gastrointestinal Cancers Symposium 67
Oct 16, 2017: Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma 68
Oct 16, 2017: Ipsen announces that phase 3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma 70
Sep 09, 2017: Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 71
Sep 06, 2017: Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress 73
Sep 04, 2017: Ipsen To Present 7 Abstracts on Cabometyx at European Society of Medical Oncology congress 74
Aug 01, 2017: Exelixis to Feature Presentations on Cabozantinib at ESMO 2017 Congress 76
Jun 19, 2017: Ipsen and its Partner Exelixis Announce Independent Radiology Committee Review Confirms Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma 79
Jun 12, 2017: Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors 80
Jun 01, 2017: Ipsen To Present New Data of Cabometyx at ASCO 81
Feb 17, 2017: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors 83
Other Significant Developments 85
Sep 07, 2017: Exelixis Debuts New Mission-Driven Corporate Branding That Supports Upcoming Milestones and Growth Strategy 85
Appendix 86
Methodology 86
About GlobalData 86
Contact Us 86
Disclaimer 86

List of Tables
Exelixis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Exelixis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Exelixis Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Exelixis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Exelixis Enters into Agreement with Roche 11
Exelixis Enters into Agreement with Bristol-Myers Squibb 12
Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 13
Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 15
Exelixis Enters into Licensing Agreement with Invenra 17
Exelixis Enters into Licensing Agreement with Stemsynergy Therapeutics 18
Takeda Pharma Enters into Licensing Agreement with Exelixis 19
Ipsen Amends Licensing Agreement with Exelixis 20
Exelixis Raises USD155 Million in Public Offering of Shares 22
Exelixis Completes Public Offering Of Shares For US$80 Million 23
Exelixis Completes Public Offering Of Common Stock For US$147 Million 24
Exelixis Completes Public Offering Of Common Stock For US$69 Million 25
Exelixis Completes Public Offering Of Senior Convertible Notes Due 2019 For US$288 Million 27
Exelixis Inc, Key Competitors 29
Exelixis Inc, Key Employees 30
Exelixis Inc, Subsidiaries 31

List of Figures
Exelixis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Exelixis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Exelixis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Exelixis Inc (EXEL):製薬・医療:M&Aディール及び事業提携情報(Exelixis Inc (EXEL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆